IBI314 / Innovent Biologics - LARVOL DELTA

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials. (PubMed, Virol J) - P1/2 | "Together, our approach revealed the possibility of engineering of existing antibodies to broad-spectrum mAbs as potential therapeutic or prophylactic agents for COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 (clinicaltrials.gov) - P1/2 | N=248 | Terminated | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Completed ➔ Terminated; The company decision that terminated the further develop of the molecule and had notified FDA about the termination as well.

Trial termination • Infectious Disease • Novel Coronavirus Disease

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - P1/2 | N=222 | Terminated | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Terminated; Due to the company's development strategy adjustment, Innovant Biologics decided not to continue this study after consultation with investigators.

Trial termination • Infectious Disease • Novel Coronavirus Disease

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 (clinicaltrials.gov) - P1/2 | N=248 | Completed | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Completed | Trial completion date: Jul 2022 ➔ Nov 2022

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

The efficacy and safety of IBI314 on Delta and Omicron variant of SARS-CoV-2: first-in-human evidence. (PubMed, J Infect) - No abstract available

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 (clinicaltrials.gov) - P1/2; N=240; Recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • PCR

A Safety, Tolerability, and Efficacy Study of IBI314 in Mild to Moderate Patients With COVID-19 (clinicaltrials.gov) - P1/2; N=222; Not yet recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • PCR

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 (clinicaltrials.gov) - P1/2; N=240; Not yet recruiting; Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • PCR